In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on KemPharm (KMPH), with a price target of $2.50. The company’s shares closed last Monday at $0.45, equals to its 52-week low of $0.45.
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 7.1% and a 53.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Zynerba Pharmaceuticals.
KemPharm has an analyst consensus of Moderate Buy, with a price target consensus of $4.02.
See today’s analyst top recommended stocks >>
Based on KemPharm’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $2.72 million. In comparison, last year the company had a GAAP net loss of $15.07 million.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KMPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
